sustain
jak trade pipelin improvingpt
compani
myeloprolif neoplasm mpn busi model expand
area project diseas encourag plan
ruxolitinib life-cycle manag includ new formul indic
combin pursuit geneticallli defin tumor-agnost indic
pemigatinib multipl oncolog auto-immun indic parsaclisib
develop potenti first-in-class oral inibitor updat sale
earn estim drive new price target vs prior
maintain perform rate base valuat detail insid
manag provid increment inform life-cycle manag
plan ruxolitinib includ new formul indic combin
exhibit encourag manag outlin growth beyond
june expir ruxolotinib composit matter patent us
develop two once-daili sustained-releas sr formul ruxolitinib
conduct studi compar immediate-releas ir
ruxolitinib sr deliv smoother pk profil vs ir exhibit efficaci result
suggest increas therapeut index formul select
develop
optimist pipelin project diseas includ
new jak indic gvhd autoimmun disord new
molecul develop oncolog non-oncolog indic gvhd
area focu year feb pdufa ruxolitinib result
ruxolitinib itacinib later year exhibit
pemigatinib oral potent select fgfr inhibitor develop
cholangiocarcinoma bladder cancer anoth rare indic
encourag recent plan develop pemigatinib tumor-agnost
genet defin popul exhibit molecul parsaclisib
variou autoimmun disord exhibit
manag also provid increment detail spend
controversi encourag manag willing address
spend investor rais concern look forward
manag updat along result meanwhil remain perform
rate see share fairli valu
year price histori incyt
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur
develop epacadostat discontinu
regulatori approv launch baricitinib
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig partner candid baricitinib oral
therapi ra may drive revenu upsid eventu
deep promis pipelin includ capmatinib
divers pipelin driven take-over specul lead
valuat premium fair market valuat view
gvhd result
feb potenti fda approv jakafi agvhd
estim sinc pdufa sunday
greater expect advanc pipelin asset
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale could peak
us includ peak royalti ex-u sale see iclusig olumi smaller contributor revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit articul long-term strategi grow sustain myeloprolif
neoplasm mpn busi model includ life cycl manag ruxolitinib
pharmacokinet compar immedi releas ruxolitinib
exhibit encourag inci pipelin progress project indic
exhibit gvhd particular area interest potenti fda decis jakafi
exhibit plan pursu tumor agnost indic pemigatinib
exhibit beyond oncolog inci pipelin expand new area
exhibit dcf valuat support new pt vs prior
discount analysisoppenheim co except per-shar data revenu chang work work capit valu growth valu oppenheim co estimatesequ valu per sharetermin valu growth rate probabl
thousand except per share
product royalti revenu olumi us eu row
jakafi essenti thrombocythemia et
jakafi gvhd
probabl success
probabl success
probabl success
probabl success
probabl success
mileston contract research
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
ep basic dilut
ep non-gaap basic dilut
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
